Global firms could enter hepatitis vaccine market

Following the suspension of local suppliers, GSK, J & J may win contracts

Despite Chinese health authorities' claim that there's no link between hepatitis B vaccinations and several babies' deaths, parents' confidence in domestic vaccinations has been shaken - and that's boosting the outlook for overseas drug companies.

Many people "are willing to pay more for the higher quality and safety of imported vaccines", said Guo Wei, an analyst with Ipsos, a global market-research company.